Supriya Lifescience Q3FY26 Results: Revenue Up 11.2% YoY to ₹2,064.4 Cr, PAT ₹496.8 Cr
Supriya Lifescience reported Q3 FY26 revenue of ₹2,064.4 crore, up 11.2% YoY. PAT was ₹496.8 crore, a 6.2% increase. For 9M FY26, revenue reached ₹5,513.5 crore. The company has secured a 10-year CMO contract with a European firm for exclusive API supply, expected to generate ₹60 crore annually from FY27. Manufacturing capacity has been enhanced by over 55%.
The revenue growth is positive, but the PAT decline for the nine-month period and the relatively modest PAT growth for the quarter limit the immediate impact. The long-term contract is a significant positive factor.
The company reported positive year-on-year revenue growth for the quarter and highlighted a significant long-term contract, indicating a positive outlook.
Supriya Lifescience Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a revenue of ₹2,064.4 million (₹2064.4 crore) for Q3 FY26, marking an 11.2% increase year-on-year from ₹1,856.5 million in Q3 FY25. EBITDA stood at ₹720.8 million, a 9.3% rise YoY. Profit After Tax (PAT) for the quarter was ₹496.8 million, up 6.2% from ₹467.8 million in the same period last year.
For the nine months ended December 31, 2025 (9M FY26), revenue grew by 7.6% YoY to ₹5,513.5 million (₹5513.5 crore) from ₹5,123.8 million in 9M FY25. EBITDA for the nine-month period was ₹1,964.3 million, a marginal 1.7% increase YoY. PAT for 9M FY26 declined by 2.0% to ₹1,348.9 million from ₹1,375.8 million in 9M FY25.
The company's investor presentation also highlights its business mix, with Asia contributing significantly to revenue. Key therapeutic areas include Anesthetic, Analgesic, Anti-Histamine, and Vitamins. Supriya Lifescience emphasizes its backward integrated business model, global presence in over 120 countries, and advanced manufacturing facilities. The company is expanding its R&D capabilities and exploring CMO/CDMO opportunities, including a 10-year contract with a leading European company for exclusive API supply, expected to generate peak revenue of ₹60 crore per year starting from FY27. The company has also commissioned a new Module E Production Block, increasing its capacity by over 55% to 932 KLPD.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.